Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical Technology

Roche believes its new BTK-degrader bexobrutideg will outperform approved BTK-inhibitors in B-cell malignancies. Roche believes its new BTK-degrader bexobrutideg will outperform approved BTK-inhibitors in B-cell malignancies. Roche and Nurix will co-commercialise bexobrutideg in the US across all indications, while the Swiss drugmaker will market the drug in the rest of the world. Credit: Taljat David/Shutterstock.com. Roche has bought partial rights to Nurix Therapeutics’ bexobrutideg in a deal worth up to $2.3bn that will see the big pharma company help advance a drug that could outperform existing Bruton’s Tyrosine Kinase (BTK)-targeted therapeutics. The licensing and collaboration agreement involves Roche paying $700m…

Source: Pharmaceutical Technology